AH-HA: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

Sponsor

Wake Forest University Health Sciences (Other)

Overall Status

Enrolling by invitation

CT.gov ID

NCT03935282

Collaborator

National Cancer Institute (NCI) (NIH), Washington University School of Medicine (Other), University of Texas Southwestern Medical Center (Other)

640

Enrollment

Locations

Arms

31.9

Anticipated Duration (Months)

Patients Per Site

2.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin lymphoma cancer survivors (N=600) receiving survivorship care in community oncology practices, using a group-randomized trial design (6 intervention practices and 6 usual care practices). Our central hypothesis is that the AH-HA tool will increase (1) cardiovascular health (CVH) discussions among survivors and oncology providers, (2) referrals and visits to primary care and cardiology (care coordination), and (3) cardiovascular (CV) risk reduction and health promotion activities compared to usual care.

Condition or Disease	Intervention/Treatment	Phase
Breast Neoplasm Prostatic Neoplasm Colorectal Neoplasms Endometrial Neoplasms Hodgkin Disease Non Hodgkin Lymphoma	Other: AH-HA Tool in the EPIC EHR	N/A

Detailed Description

In this hybrid effectiveness-implementation group-randomized clinical trial, 6 intervention practices will receive an EHR-based cardiovascular health assessment tool (Automated Heart Health Assessment for Survivors: AH-HA) and 6 practices will serve as usual care (control) practices without access to the AH-HA tool. AH-HA renders a visual, interactive display of CVH risk factors, automatically populated from the EHR. This tool was first implemented in primary care and now incorporates EHR data on receipt of cancer treatments with cardiotoxic potential. Providers at each intervention site will be trained to use the tool during routine follow-up care with survivors. Eligible survivors with breast, prostate, colorectal, endometrial, or Hodgkin and non-Hodgkin lymphoma cancer (n=600) will provide baseline data before and immediately after seeing their oncology provider and complete 6-month and 1-year study follow-up visits. The study team will compare changes in outcomes from baseline to 1-year in survivors at the intervention and usual care clinics using data from survivor self-reports and the EHR. The primary outcome is CVH discussions defined as the number of patient-reported discussions with their provider regarding up to seven non-ideal CVH conditions identified for that patient during oncology visits. Secondary outcomes include referrals to primary care and cardiology, provider efforts to manage CV risk, survivors' completed visits with primary care providers and cardiologists, and control of CVH factors and behaviors. Implementation metrics will be assessed using data from the EHR and semi-structured interviews with providers and administrators (n=24-30) at intervention clinics.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

640 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Supportive Care

Official Title:

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (AH-HA)

Actual Study Start Date :

Oct 1, 2020

Anticipated Primary Completion Date :

May 31, 2023

Anticipated Study Completion Date :

May 31, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Intervention - AH-HA tool With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.	Other: AH-HA Tool in the EPIC EHR The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
No Intervention: Usual Care Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.

Arm

Intervention/Treatment

Experimental: Intervention - AH-HA tool

With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.

Other: AH-HA Tool in the EPIC EHR

The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.

No Intervention: Usual Care

Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.

Outcome Measures

Primary Outcome Measures

Proportion of patients reporting at least one non-ideal or missing CVH topic [Baseline]
Discussion of non-ideal cardiovascular health (CVH) factors (yes or no). CVH discussions will be defined as patient-reported discussions with their provider for any of the seven non-ideal CVH conditions identified for that patient. Conditions include CVH factors (cholesterol, blood pressure, glucose/hemoglobin A1c) and CVH behaviors (body mass index, smoking, diet, and physical activity). Measured using survivor survey (discussions, diet, and primary care) and EHR for other CVH factors.

Secondary Outcome Measures

Number of referrals to primary care and cardiology to manage CV risk [1 year]
Medical chart abstraction of referrals and communication with providers regarding CVH at each survivor visit.
Number of CVH-relevant labs and treatments to manage CV risk [1 year]
Medical chart abstraction.
Completed visits with primary care providers and cardiology [1 year]
Medical chart abstraction of referrals and communication with providers regarding CVH at each survivor visit.
CVH behaviors recorded in the past year [1 year]
Medical chart abstraction; Patient survey as secondary, verification source. Measured using smoking status, BMI, physical activity, and healthy diet.
CVH factors recorded in the past year [1 year]
Medical chart abstraction; Patient survey as secondary, verification source. Measured using total cholesterol, blood pressure, and fasting plasma glucose/Alc.
Patient perception and knowledge of CV risks [Baseline, 6 months, 1 year]
Measured using structured survivor survey. Health knowledge questions were adapted from a survey assessing the relative risk of cancer and cardiovascular disease in United States populations.Minimum score is 0, maximum score is 3 and answer is the total number of questions where a patient responded agree or strongly agree.
Proportion of survivors for whom AH-HA is utilized [1 year]
We will capture the number of eligible patient visits during which the AH-HA tool was used in intervention clinics and the total number of eligible visits to calculate the proportion of patients where AH-HA was utilized.
Measure of tool acceptability with Tool Assessment [Baseline]
In the Baseline: Post-Visit Survey, survivors will complete a Tool Assessment questionnaire assessing whether or not they recall seeing or discussing the AH-HA tool with their provider and five questions assessing: how much they liked the tool, how helpful it was, how easy it was to understand, how much it improved their understanding, and if they would like to use this tool in the future. Patients will respond to 5 questions on a scale from strongly agree to strongly disagree.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

= 6 months post-potentially curative cancer treatment for breast, prostate, colorectal, or endometrial cancers or Hodgkin and non-Hodgkin lymphomas. Ongoing hormonal therapies such as tamoxifen, aromatase inhibitors, or androgen deprivation are allowed.
Scheduled for a routine cancer-related follow-up care visit within the next 30 days with a provider who received training to use AH-HA.
Able and willing to complete a follow-up assessment in one year.
Survivors must have no evidence of disease at the time of last medical visit for all cancers, except non-melanoma skin disease.
Age >= 18 years.
Able to understand and willing to provide verbal informed consent.

Exclusion Criteria:

Survivors will be excluded if they have a history of cancer recurrence for any cancer other than non-melanoma skin disease.
Prostate patients on active surveillance will be excluded.
Survivor does not speak English or Spanish.
Survivors who are currently on another interventional protocol in which cardiovascular risk factors (e.g., blood pressure, smoking, diet, physical activity) are being addressed, as per patient self-report or research staff members' knowledge at the time of consent.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mercy Hospital Fort Smith	Fort Smith	Arkansas	United States	72903
2	Oncology Associates at Mercy Medical Center	Cedar Rapids	Iowa	United States	52403
3	Mercy Hospital Springfield	Springfield	Missouri	United States	65804
4	Community Medical Center	Scranton	Pennsylvania	United States	18510
5	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre	Pennsylvania	United States	18711
6	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis	Tennessee	United States	38120
7	Baptist Memorial Hospital for Women	Memphis	Tennessee	United States	38120
8	ThedaCare Regional Cancer Center	Appleton	Wisconsin	United States	54911